The stock of Editas Medicine Inc (NASDAQ:EDIT) last traded at $1.97, down -9.63% from the previous session.
EDIT stock price is now 27.73% away from the 50-day moving average and -5.91% away from the 200-day moving average. The market capitalization of the company currently stands at $164.91M.
With the price target of $3, H.C. Wainwright recently initiated with Buy rating for Editas Medicine Inc (NASDAQ: EDIT). , while ‘Truist’ rates the stock as ‘Hold’
In other news, Parison Amy, SVP, Chief Financial Officer sold 446 shares of the company’s stock on Jun 03 ’25. The stock was sold for $769 at an average price of $1.72. Upon completion of the transaction, the SVP, Chief Financial Officer now directly owns 17,506 shares in the company, valued at $34486.82. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 03 ’25, EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold 726 shares of the business’s stock. A total of $1,252 was realized by selling the stock at an average price of $1.72. This leaves the insider owning 69,519 shares of the company worth $0.14 million. A total of 0.91% of the company’s stock is owned by insiders.
During the past 12 months, Editas Medicine Inc has had a low of $0.91 and a high of $6.07. As of last week, the company has a debt-to-equity ratio of 0.50, a current ratio of 3.08, and a quick ratio of 3.08. The fifty day moving average price for EDIT is $1.5423 and a two-hundred day moving average price translates $2.093675 for the stock.
The latest earnings results from Editas Medicine Inc (NASDAQ: EDIT) was released for 2025-03-31. The net profit margin was -701.06% and return on equity was -140.82% for EDIT. The company reported revenue of $4.66 million for the quarter, compared to $1.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 310.4 percent.
